我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

缬沙坦对高血压左室肥厚患者QT离散度及室性心律失常的影响(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2003年第3期
页码:
236-238
栏目:
临床研究
出版日期:
2003-05-01

文章信息/Info

Title:
The effects of valsartan on QT interval dispersion and ventricular arrhythmia in patients with left ventricular hypertrophy caused by hypertension
作者:
杨沙宁1; 黄从新1; 金立军2; 夏豪1; 周林2; 刘冬舟1
1.武汉大学人民医院心内科,湖北武汉430060;2.湖北省荆州市第一人民医院,湖北荆州434000
Author(s):
YANG Sha-ning1; HUANG Cong-xin1; JIN Li-jun 2;  XIAHao 1; ZHOU Lin2; LIU Dong-zhou1
1.Department of Cardiology,People's Hospital of Wu han University,Wu han,Hu bei430060,China
关键词:
高血压; QT间期离散度; 心律失常; 室性
Keywords:
hypertension; QT dispersion; arrhythmia; ventricula
分类号:
R544.1
DOI:
-
文献标识码:
A
摘要:
目的:探讨缬沙坦(Valsartan,Val)对高血压病左室肥厚(LVH)患者左室质量指数(LVMI)、心率校正的QT离散度(QTcd)及室性心律失常(VA)的影响。方法:高血压病LVH患者共55例,随机分为常规治疗组(Rou组,n=30),缬沙坦治疗组(Val组,n=25)。两组分别于治疗前、治疗1年后用彩色多普勒Penn法测定LVMI,分析体表标准12导联心电图QTcd并用Holter记录VA发生的情况。结果:LVH患者LVMI与QTcd间有显著相关性(r=0.36,P<0.01)。Rou组治疗前后LVMI为150±16g·m-2vs149±16g·m-2(P>0.05);Val组治疗前、后LVMI为152±17g·m-2vs139±15g·m-2(P<0.01)。Rou组治疗前后QTcd为74±12msvs72±12ms(P >0.05),Val组治疗前后QTcd为73±12msvs65±9ms(P<0.05)。治疗前Rou组与Val组间QTcd无显著性差异(P>0.05),治疗后两组间QTcd存在显著性差异(P<0.05)。Rou组及Val组治疗前VA恶性程度无显著性差异(P>0.05),治疗后两组间VA恶性程度比较有显著性差异(P<0.05)。结论:Val治疗可显著降低LVMI和QTcd,从而降低VA的恶性程度。
Abstract:
AIM:To investigate the effect of valsartan(Val) on left ventricular mass index (LVMI), heart rate corrected QT interval dispersion (QTcd) and ventricular arrhythmia(VA) in patients with left ventricular hypertrophy (LVH) caused by essential hypertension.METHODS: 55 hypertension patients with LVH were divided randomly into two groups.30 patients in Rou group were treated routinely.25 patients in Val group were treated with routine drugs plus val. LVMI,QTcd of 12-lead surface ECG and VA malignant degree recorded by Holter were analyzed before and 1 year after the therapy.RESULTS:In the Rou group,the change of QTcd before and after the therapy was not significant(74±12msvs72±12ms,P>0.05).In the Val group,the change of QTcd was significant before and after the therapy (73±12msvs65±9ms,P<0.05). Before the therapy QTcd and the malignant degree of VA between the two groups were not significantly different. But both of the two indexes between the two groups were significantly different after the therapy.CONCLUSION:Treatment with Val can significantly reduce the QTcd and the malignant degree of VA in patients with LVH caused by hypertension

参考文献/References

[1]Thvrmann PA,Kenedi P,Schmidt A,et al.Infuence of the angiotensin Ⅱ antagonist vasartan on left ventricular hypertrophy in patients with essential hypertension[J].Circulation,1998,98:2037-2042.

[2]张抒扬,戴玉华.全国高血压左室肥厚临床及基础研讨会纪要[J].中华心血管病杂志,1994,33:139-140

.[3]马奕,郭映春,刘燕,等.QT间期及离散度测定的方法学研究和正常值[J].心脏起搏与电生理志,1995,9:130-132.

[4]Muller DN,Mervaala EM,Dechend R,et al.Angiotensin II(AT(1))receptor blockade reduces vascular tissue factor in angiotensin II-induced cardiac vasculopathy [J]. Clin Exp Pharmacol Physiol,2000,27:642-646.

[5]Carey RM,Wang ZQ,Siragy HM.Update: role of the angiotensin type-2 (AT(2)) receptorin blood pressure regulation [J]. Curr Hypertens Rep,2000,2:198-201.

[6] Tea BS,Der Sarkissian S,Touyz RM,et al.Proapoptotic and growth-inhibitory role of angiotensin Ⅱ type2 receptor in vascular smooth muscle cells of spontaneously hypertensive rats in vivo [J]. Hypertension,2000,35:1069-1073

备注/Memo

备注/Memo:
收稿日期：2002-1-15.
更新日期/Last Update: 2003-05-01